Featured Stories
Insurer Incentives For Lower-Cost HIV Drugs Not Seen As Significant Threat For Gilead, ViiV
UnitedHealthcare offers HIV-infected patients a financial incentive to switch to lower-cost therapy, including generic TDF, but analysts suspect the savings won’t be enough to encourage much switching away from Gilead’s single-tablet regimens.
Amarin's REDUCE-IT Data For Vascepa May Be Game-Changing, But Not Without Controversy
CVOT results for Amarin's fish-oil pill show an unprecedented reduction in cardiovascular deaths. While questions have been raised about an LDL increase in the placebo group, an investigator says the overall results are too good to be explained by a well-known mineral oil effect.
Mylan/Theravance’s Yupelri Will Launch Late This Year To Address COPD Niche
Yupelri was approved by the US FDA as the first nebulized long-acting muscarinic antagonist for once-daily treatment of chronic obstructive pulmonary disease.
Latest News
Recent Tweets from ScripCase Study: Broad Thinking Yields Big Results
There are numerous details when considering product packaging that require both creative thinking and feature prioritization. Rather than developing a standard solution for the current need, it’s imperative to think broadly and design options that are cost-effective, simplify operations and save time and/or resources.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Back In Fashion? Boston’s CBO Talks Turkey On Reinvigorating Pharma’s Unwanted Assets
Constantine Chinoporos, Boston Pharmaceuticals’ CBO, talks to Scrip about its deal strategy and how it intends to build its pipeline over the next few years, liberated from the constraints of portfolio management.
Accera Sees New Potential As It Renames, Expands To Asia To Progress Alzheimer’s Asset
The US bioventure Accera, hit by a Phase III failure for its lead candidate last year, is expanding into Asia and renaming itself as it remains hopeful of progressing its core investigational asset in a targeted population of Alzheimer’s disease patients.
New Year Present For Takeda As Shire Close Nears?
Takeda is hoping to start 2019 with a bang, saying its huge acquisition of Shire might become a done deal as early as January 8. Speculation continues meanwhile on possible post-merger divestments to help pay down associated debt.
Coherus Gears Up For January Udenyca Launch, Prices Biosimilar At 33% Discount To Neulasta
Buoyed by the market share held by biosimilars of the short-acting neutropenia drug Neupogen, Coherus hopes its Udenyca price, contracts and services will give its biosimilar a significant share of the market for the longer-acting Neulasta.
Migraine Market Gets Competitive With Second, Third CGRP Inhibitor Launches
CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.
'Slow Money As Bad As No Money' – SMEs Struggle For Superbug Funds
The key to getting funding for small biotechs which focus on tackling antimicrobial resistance is to get private investors interested to top up 'push' incentives from the likes of CARB-X, the AMR Centre's Peter Jackson tells Scrip.
Tech Transfer Roundup: J&J Houses JPOD Incubator At University Of Pennsylvania
Pascal and Oblato separately license therapeutic candidates for glioblastoma multiforme, while Cabaletta emerges from UPenn with novel program for CAAR-T therapies in B-cell mediated autoimmune disease.
Deal Watch: Amgen Outsources Celiac Drug To Provention; Lilly, NextCure Will Co-Discover IO Drugs
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
‘Drastic’ Japan Price Reforms Hitting R&D Incentives, Plans - EFPIA
European research-based pharma group proposes reconsideration of Japan’s revised pricing system, warning it is already affecting corporate R&D decisions and will stifle industry investment, innovation and patient access to new therapies if incentives are not improved.
AZ's Lynparza PARP Lead Likely To Lengthen With FDA Priority Review
Despite suffering a setback at the hands of NICE, AstraZeneca's ambitious plans for Lynparza have been boosted by the FDA agreeing to speed up a review of the recent SOLO-1 data which took ESMO by storm last month.
Speedy NICE Support For Eisai's Lenvima In Liver Cancer
It took NICE nearly three years to offer routine access to Lenvima for thyroid cancer but it has taken just three months from European approval to recommend the drug for advanced or unresectable hepatocellular carcinoma.
China Set To Become Global Drug Innovation Center
A London conference was told that Chinese trends in modernizing healthcare and life sciences innovation will soon produce high-quality 'made in China' medicines for global export.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Pipeline Watch: Phase III Print-Outs For Tivozanib, Dulaglutide And VTS-270
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Gilead’s FXR Agonist Posts Questionable Results In NASH, But Offers Hope In PSC
Although GS-9674’s efficacy data don’t appear as promising as that for Intercept’s competing FXR agonist OCA, Gilead seems to be building an argument that its drug has a better combination of efficacy and safety.
Genkyotex Plans 'Solo' Pivotal Trials After Lead Product Hits Phase II PBC Targets
The CEO Genkyotex says its lead molecule therapy's mechanism of action has been validated by good short-term effects on patients with the autoimmune liver disease primary biliary cholangitis in a Phase II trial.
Watch Out GSK: Vectura And Hikma Target Ellipta Portfolio
Vectura and Hikma could have generic versions of GSK's Ellipta portfolio ready for marketing when patent protection expires.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.